Efficacy analysis of CDK4/6 inhibitors (CDKi) plus endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study

被引：0

作者：

Tolosa Ortega, Pablo

Pascual, Tomas

Hernando, Cristina

Servitja, Sonia

Fernandez-Abad, Maria

Braso-Maristany, Fara

Benitez Fuentes, Javier David

Lema, Laura

Parrilla Rubio, Lucia

Ruano, Yolanda

Maria Roncero, Ana

Sanchez-Bayona, Rodrigo

Alva Bianchi, Manuel

Villacampa, Guillermo

Cobos-Fernandez, Maria Angeles

del Rocio Moreno, Maria

Canes, Jordi

Salvador, Fernando

Prat, Aleix

Ciruelos, Eva M.

机构：

[1] Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain

[2] Hosp Clin Barcelona, August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Dept Med Oncol,SOLTI Breast Canc Cooperat Grp, Barcelona, Spain

[3] Hosp Clin Univ Valencia, Dept Med Oncol, Biomed Res Inst INCLIVA, Valencia, Spain

[4] Hosp Mar, Barcelona, Spain

[5] Ramon y Cajal Univ Hosp, Dept Med Oncol, Madrid, Spain

[6] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[7] August Pi & Sunyer Biomed Res Inst IDIBAPS, Barcelona, Spain

[8] Hosp Clin San Carlos, Dept Med Oncol, IdISSC, Madrid, Spain

[9] 12 Octubre Univ Hosp, Madrid, Spain

[10] Hosp Univ 12 Octubre, Dept Pathol, Madrid, Spain

[11] Hosp Univ 12 Octubre Res Inst, Mol Pathol Unit, Madrid, Spain

[12] SOLTI Canc Res Grp, Barcelona, Spain

[13] Univ Hosp 12 Octubre, Dept Med Oncol, Breast Canc Unit, GEICAM Spanish Breast Canc Grp, Madrid, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1065

引用

页数：1

共 50 条

[21] CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials
Messina, Carlo
Cattrini, Carlo
Buzzatti, Giulia
Cerbone, Luigi
Zanardi, Elisa
Messina, Marco
Boccardo, Francesco
BREAST CANCER RESEARCH AND TREATMENT, 2018, 172 (01) : 9 - 21
[22] Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
Lin, Mingxi
Chen, Yang
Jin, Yizi
Hu, Xichun
Zhang, Jian
JOURNAL OF CANCER, 2020, 11 (24): : 7127 - 7136
[23] CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis
Agostinetto, E.
Vian, L.
Caparica, R.
Bruzzone, M.
Ceppi, M.
Lambertini, M.
Ponde, N.
de Azambuja, E.
ESMO OPEN, 2021, 6 (02)
[24] CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects
Wekking, Demi
Leoni, Vera Piera
Lambertini, Matteo
Dessi, Mariele
Pretta, Andrea
Cadoni, Andrea
Atzori, Luigi
Scartozzi, Mario
Solinas, Cinzia
CYTOKINE & GROWTH FACTOR REVIEWS, 2024, 75 : 57 - 64
[25] Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2-breast cancer: an umbrella review
Pu, Dongqing
Xu, Debo
Wu, Yue
Chen, Hanhan
Shi, Guangxi
Feng, Dandan
Zhang, Mengdi
Liu, Zhiyong
Li, Jingwei
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (01)
[26] Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).
Sonke, Gabe S.
Van Ommen-Nijhof, Annemiek
Wortelboer, Noor
van der Noort, Vincent
Swinkels, Astrid C. P.
Blommestein, Hedwig M.
Beeker, Aart
Beelen, Karin
Hamming, Lisanne C.
Heijns, Joan B.
Honkoop, Aafke H.
De Jong, Paul C.
Van Rossum-Schornagel, Quirine C.
van Schaik-van de Mheen, Christa
Tol, Jolien
Tromp-Van Driel, Cathrien
Vrijaldenhoven, Suzan
Van Leeuwen-Stok, A. Elise
Konings, Inge
Jager, Agnes
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA1000 - LBA1000
[27] Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).
Sonke, Gabe S.
Van Ommen-Nijhof, Annemiek
Wortelboer, Noor
van der Noort, Vincent
Swinkels, Astrid C. P.
Blommestein, Hedwig M.
Beeker, Aart
Beelen, Karin
Hamming, Lisanne C.
Heijns, Joan B.
Honkoop, Aafke H.
De Jong, Paul C.
Van Rossum-Schornagel, Quirine C.
van Schaik-van de Mheen, Christa
Tol, Jolien
Tromp-Van Driel, Cathrien
Vrijaldenhoven, Suzan
Van Leeuwen-Stok, A. Elise
Konings, Inge
Jager, Agnes
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[28] Copy loss enrichment at metastatic disease progression in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer patients treated with endocrine therapy and CDK4/6 inhibition
Davis, A. A.
Luo, J.
Zheng, T.
Dai, C.
Suresh, R.
Ademuyiwa, F. O.
Rigden, C.
Clifton, K.
Weilbaecher, K.
Frith, A. E.
Tandra, P.
Summa, T.
Thomas, S.
Peterson, L.
Wang, X.
Du, P.
Jia, S.
King, B. L.
Krishnamurthy, J.
Ma, C. X.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S587 - S588
[29] Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
Zattarin, Emma
Mariani, Luigi
Menichetti, Alice
Leporati, Rita
Provenzano, Leonardo
Ligorio, Francesca
Fuca, Giovanni
Lobefaro, Riccardo
Lalli, Luca
Vingiani, Andrea
Nichetti, Federico
Griguolo, Gaia
Sirico, Marianna
Bernocchi, Ottavia
Marra, Antonio
Corti, Chiara
Zagami, Paola
Agostinetto, Elisa
Jacobs, Flavia
Di Mauro, Pierluigi
Presti, Daniele
Sposetti, Caterina
Giorgi, Carlo Alberto
Guarneri, Valentina
Pedersini, Rebecca
Losurdo, Agnese
Generali, Daniele
Curigliano, Giuseppe
Pruneri, Giancarlo
de Braud, Filippo
Dieci, Maria Vittoria
Vernieri, Claudio
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[30] Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
Zattarin, Emma
Mariani, Luigi
Menichetti, Alice
Leporati, Rita
Provenzano, Leonardo
Ligorio, Francesca
Fuca, Giovanni
Lobefaro, Riccardo
Lalli, Luca
Vingiani, Andrea
Nichetti, Federico
Griguolo, Gaia
Sirico, Marianna
Bernocchi, Ottavia
Marra, Antonio
Corti, Chiara
Zagami, Paola
Agostinetto, Elisa
Jacobs, Flavia
Di Mauro, Pierluigi
Presti, Daniele
Sposetti, Caterina
Giorgi, Carlo Alberto
Guarneri, Valentina
Pedersini, Rebecca
Losurdo, Agnese
Generali, Daniele
Curigliano, Giuseppe
Pruneri, Giancarlo
de Braud, Filippo
Dieci, Maria Vittoria
Vernieri, Claudio
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15

← 1 2 3 4 5 →